Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma

Tools

Gallagher, A., Edwards, M. ORCID: 0000-0001-5190-7073, Nair, P., Drew, S., Vyas, A., Sharma, R., Marsden, P.A., Wang, R. and Evans, D.J., 2021. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database of Systematic Reviews, 2021 (10): CD012929. ISSN 1469-493X

Preview

Text
1484457_Edwards.pdf - Published version
Download (1MB) | Preview

Official URL: https://doi.org/10.1002/14651858.cd012929.pub2

Abstract

Background: Targeting the immunoglobulin E pathway and the interleukin‐5 pathway with specific monoclonal antibodies directed against the cytokines or their receptors is effective in patients with severe asthma. However, there are patients who have suboptimal responses to these biologics. Since interleukin‐4 and interleukin‐13, signalling through the interleukin‐4 receptor, have multiple effects on the biology of asthma, therapies targeting interleukin‐4 and ‐13 (both individually and combined) have been developed.

Objectives: To assess the efficacy and safety of anti‐interleukin‐13 or anti‐interleukin‐4 agents, compared with placebo, anti‐immunoglobulin E agents, or anti‐interleukin‐5 agents, for the treatment of children, adolescents, or adults with asthma.

Search methods: We identified studies from the Cochrane Airways Trials Register, which is maintained by the Information Specialist for the Group and through searches of the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. The search was carried out on the 16 October 2020.

Selection criteria: We included parallel‐group randomised controlled trials that compared anti‐interleukin‐13 or ‐4 agents (or agents that target both interleukin‐13 and interleukin‐4) with placebo in adolescents and adults (aged 16 years or older) or children (younger than 16 years), with a diagnosis of asthma; participants could receive their usual short‐ or long‐acting medications (e.g. inhaled corticosteroids (ICS), long‐acting beta adrenoceptor agonists (LABA), long‐acting muscarinic antagonists (LAMA), and/or leukotriene receptor antagonists) provided that they were not part of the randomised treatment.

Data collection and analysis: We used standard methods expected by Cochrane.

Main results: We identified and included 41 RCTs. Of these, 29 studies contributed data to the quantitative analyses, randomly assigning 10,604 people with asthma to receive an anti‐interleukin‐13 (intervention) or anti‐interleukin‐4 agent (intervention), or placebo (comparator). No relevant studies were identified where the comparator was an anti‐immunoglobulin agent or an anti‐interleukin‐5 agent. Studies had a duration of between 2 and 52 (median 16) weeks. The mean age of participants across the included studies ranged from 22 to 55 years. Only five studies permitted enrolment of children and adolescents, accounting for less than 5% of the total participants contributing data to the present review. The majority of participants had moderate or severe uncontrolled asthma. Concomitant ICS use was permitted or required in the majority (21 of 29) of the included studies. The use of maintenance systemic corticosteroids was not permitted in 19 studies and was permitted or required in five studies (information not reported in five studies). Regarding the most commonly assessed anti‐interleukin‐13/‐4 agents, four studies evaluated dupilumab (300 mg once every week (Q1W), 200 mg once every two weeks (Q2W), 300 mg Q2W, 200 mg once every four weeks (Q4W), 300 mg Q4W, each administered by subcutaneous (SC) injection); eight studies evaluated lebrikizumab (37.5 mg Q4W, 125 mg Q4W, 250 mg Q4W each administered by SC injection); and nine studies (3259 participants) evaluated tralokinumab (75 mg Q1W, 150 mg Q1W, 300 mg Q1W, 150 mg Q2W, 300 mg Q2W, 600 mg Q2W, 300 mg Q4W, each administered by SC injection; 1/5/10 mg/kg administered by intravenous (IV) injection); all anti‐interleukin‐13 or‐4 agents were compared with placebo.

The risk of bias was generally considered to be low or unclear (insufficient detail provided); nine studies were considered to be at high risk for attrition bias and three studies were considered to be at high risk for reporting bias.

The following results relate to the primary outcomes. The rate of exacerbations requiring hospitalisation or emergency department (ED) visit was probably lower in participants receiving tralokinumab versus placebo (rate ratio 0.68, 95% CI 0.47 to 0.98; moderate‐certainty evidence; data available for tralokinumab (anti‐interleukin‐13) only). In participants receiving an anti‐interleukin‐13/‐4 agent, the mean improvement versus placebo in adjusted asthma quality of life questionnaire score was 0.18 units (95% CI 0.12 to 0.24; high‐certainty evidence); however, this finding was deemed not to be a clinically relevant improvement. There was likely little or no difference between groups in the proportion of patients who reported all‐cause serious adverse events (anti‐interleukin‐13/‐4 agents versus placebo, OR 0.91, 95% CI 0.76 to 1.09; moderate‐certainty evidence).

In terms of secondary outcomes, there may be little or no difference between groups in the proportion of patients who experienced exacerbations requiring oral corticosteroids (anti‐interleukin‐13/‐4 agents versus placebo, rate ratio 0.98, 95% CI 0.72 to 1.32; low‐certainty evidence). Anti‐interleukin‐13/‐4 agents probably improve asthma control based on asthma control questionnaire score (anti‐interleukin‐13/‐4 agents versus placebo, mean difference ‐0.19; 95% CI ‐0.24 to ‐0.14); however, the magnitude of this result was deemed not to be a clinically relevant improvement. The proportion of patients experiencing any adverse event was greater in those receiving anti‐interleukin‐13/‐4 agents compared with those receiving placebo (OR 1.16, 95% CI 1.04 to 1.30; high‐certainty evidence); the most commonly reported adverse events in participants treated with anti‐interleukin‐13/‐4 agents were upper respiratory tract infection, nasopharyngitis, headache and injection site reaction. The pooled results for the exploratory outcome, the rate of exacerbations requiring oral corticosteroids (OCS) or hospitalisation or emergency department visit, may be lower in participants receiving anti‐interleukin‐13/‐4 agents versus placebo (rate ratio 0.71, 95% CI 0.65 to 0.77; low‐certainty evidence).

Results were generally consistent across subgroups for different classes of agent (anti‐interleukin‐13 or anti‐interleukin‐4), durations of study and severity of disease. Subgroup analysis based on category of T helper 2 (TH2) inflammation suggested greater efficacy in patients with higher levels of inflammatory biomarkers (blood eosinophils, exhaled nitric oxide and serum periostin).

Authors' conclusions: Based on the totality of the evidence, compared with placebo, anti‐interleukin‐13/‐4 agents are probably associated with a reduction in exacerbations requiring hospitalisation or ED visit, at the cost of increased adverse events, in patients with asthma. No clinically relevant improvements in health‐related quality of life or asthma control were identified. Therefore, anti‐interleukin‐13 or anti‐interleukin‐4 agents may be appropriate for adults with moderate‐to‐severe uncontrolled asthma who have not responded to other treatments. These conclusions are generally supported by moderate or high‐certainty evidence based on studies with an observation period of up to one year.